- Home
- FTFT vs XBIO Comparison
FTFT vs XBIO Comparison
Compare FTFT & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- XBIO
- Stock Information
- Founded
- FTFT N/A
- XBIO N/A
- Country
- FTFT United States
- XBIO United States
- Employees
- FTFT N/A
- XBIO N/A
- Industry
- FTFT Business Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- XBIO Health Care
- Exchange
- FTFT Nasdaq
- XBIO Nasdaq
- Market Cap
- FTFT 3.9M
- XBIO 4.2M
- IPO Year
- FTFT N/A
- XBIO N/A
- Fundamental
- Price
- FTFT $1.17
- XBIO $2.96
- Analyst Decision
- FTFT
- XBIO Hold
- Analyst Count
- FTFT 0
- XBIO 1
- Target Price
- FTFT N/A
- XBIO N/A
- AVG Volume (30 Days)
- FTFT 154.6K
- XBIO 6.9K
- Earning Date
- FTFT 05-20-2025
- XBIO 05-13-2025
- Dividend Yield
- FTFT N/A
- XBIO N/A
- EPS Growth
- FTFT N/A
- XBIO N/A
- EPS
- FTFT N/A
- XBIO N/A
- Revenue
- FTFT $2,031,913.00
- XBIO $2,582,728.00
- Revenue This Year
- FTFT N/A
- XBIO $14.23
- Revenue Next Year
- FTFT N/A
- XBIO $7.14
- P/E Ratio
- FTFT N/A
- XBIO N/A
- Revenue Growth
- FTFT N/A
- XBIO 5.63
- 52 Week Low
- FTFT $1.06
- XBIO $2.20
- 52 Week High
- FTFT $7.77
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- FTFT 35.84
- XBIO 48.28
- Support Level
- FTFT $1.46
- XBIO $2.85
- Resistance Level
- FTFT $1.57
- XBIO $3.22
- Average True Range (ATR)
- FTFT 0.14
- XBIO 0.14
- MACD
- FTFT -0.04
- XBIO -0.00
- Stochastic Oscillator
- FTFT 15.07
- XBIO 26.91
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.